Movantik
(naloxegol)ApprovedSmall molecule
Naloxegol is used to treat constipation caused by opioid pain medications. It works by blocking opioids' effects in the gut while allowing the pain relief to continue working in the brain.[2] Movantik is currently approved and in use across 7 indications[4].[1]
Movantik is one of 164 small molecule programs targeting Gastroparesis. It is currently in Approved.
7
Indications
24
Total Trials
2
Active Trials
163
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
2
Patents
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
1639 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Movantik
AAveritas Pharma, Inc.
Approved
Imjudo
AstraZenecaPreclinical
Vizimpro
PfizerPreclinical
Immunotherapy
Bristol-Myers SquibbPreclinical
Remeron
OOrganon and Co
Preclinical
PD-1 Inhibitor
Johnson & JohnsonPreclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
REGN2810
RegeneronPreclinical
Huaier Granule
QQidong Gaitianli Medicines Co., Ltd
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Constipation7 trials
Show 4 more trials
Tics2 trials
Cancer Pain1 trial
9 more indications
Non-Small Cell Lung Cancer1 trial
Postoperative Ileus1 trial
Gastrointestinal1 trial
Paralysis1 trial
Regulatory
FDA Approval Timeline[5]
Sep 16, 2014
MOVANTIK
NDA NDA204760
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Movantik drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for naloxegol. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Mu Opioid Receptor Antagonist[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- AAveritas Pharma, Inc.